Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Thoracic 2Gastrointestinal 2Dermatologic 2Breast 2Sarcoma 1Gynecologic 1

Conditions

Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 7pembrolizumab 6Radiosurgery 6Specimen Handling 5Nivolumab 5Ifosfamide 5fludarabine phosphate 4Mycophenolic Acid 4Granulocyte Colony-Stimulating Factor 4Etoposide 4Busulfan 4Sunitinib 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Paclitaxel 3Melphalan 3Magnetic Resonance Spectroscopy 3Filgrastim 3Cyclosporine 3Cryosurgery 3Carboplatin 3trastuzumab deruxtecan 2tislelizumab 2sargramostim 2pazopanib 2fludarabine 2etoposide phosphate 2cabozantinib 2Whole-Body Irradiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × ARQ 197 × Sarcoma × Clear all
NCT00557609 2013-02-08

Phase 2 Study in Patients With MiT Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 2 Completed
47 enrolled
GenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡